Delcath Systems publishes results from subgroup analyses of FOCUS study [Yahoo! Finance]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
The publication was published in the Journal of Cancer Research and Clinical Oncology. The analysis assessed efficacy and safety in subgroups of patients treated with Delcath's Hepzato Kit, a drug/device combination for liver-directed treatment of mUM patients. The Hepzato Kit is currently the only liver-directed treatment to be approved by the FDA for patients with unresectable mUM. The article provides clinically relevant subgroup analyses of key efficacy endpoints, including overall response rate, progression-free survival and overall survival, and safety categories. Prespecified subgroups included age, sex, geographic region, extent of tumor liver involvement, hepatic tumor burden, presence of extrahepatic lesions, baseline LDH and number of prior therapies. This prespecified analysis of clinically relevant subgroups included 91 patients treated in the FOCUS study. Key efficacy and safety findings include: consistent tumor response was observed regardless of age, sex, geographic r
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire
- Should New HEPZATO Subgroup Data and Delcath's Targeted Strategy Require Action From DCTH Investors? [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal MelanomaBusiness Wire
DCTH
Earnings
- 11/4/25 - In-Line
DCTH
Sec Filings
- 11/25/25 - Form 4
- 11/20/25 - Form 8-K
- 11/13/25 - Form 4
- DCTH's page on the SEC website